The Relationship Between Metformin and Serum Prostate-Specific Antigen Levels

    July 2016 in “ The Prostate ”
    Viranda H. Jayalath, Christopher Ireland, Neil Fleshner, Robert J. Hamilton, David J.A. Jenkins
    TLDR Metformin may lower PSA levels, possibly affecting prostate cancer development.
    The study found that metformin was inversely associated with serum prostate-specific antigen (PSA) levels in a dose-dependent manner, independent of other antihyperglycemic medications. This suggested that metformin might have a potential benefit in affecting prostate tumorigenesis and progression, although further investigation was needed to confirm this effect.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results